The integrated MASH platform, in one vendor.
LiverMultiScan plus PAIR-MASH™ delivers quantitative MRI, AI pathology, and central reading through a single vendor; the integrated platform pharma sponsors have been asking for. cT1 is a peer-reviewed quantitative MRI biomarker for liver tissue characterisation, with regulatory recognition across UK, EU and US and active engagement in the FDA Biomarker Qualification Programme. Used as a primary or co-primary endpoint across more than a dozen current sponsor programmes, including SYNERGY-NASH and pegozafermin trials.
PAIR-MASH adds quantitative AI assessment of ballooning, fibrosis, steatosis, and lobular, portal, and interface inflammation, on the same vendor relationship that runs the imaging endpoint. 10+ Phase 3 MASH trials supported. 20+ pathology-focused publications.
Regulatory milestone in flight. cT1 is on the FDA pathway for Reasonably Likely Surrogate Endpoint (RLSE) qualification in MASH, with full approval anticipated from 2029. Letter of Intent status in submission; sponsor decks for late-phase MASH protocols should reflect the timeline.
